Regulatory compliance – Page 40

Deviation handling weak during sponsor oversight – preventing repeat GLP findings

Strategies to Enhance Deviation Handling During Sponsor Oversight and Prevent GLP Findings In the realm of pharmaceutical manufacturing and laboratory practices, the complexity of regulated environments can often lead to…

Electronic signatures misused during inspection walkthrough – CAPA and revalidation strategy

Mitigating Misuse of Electronic Signatures During Inspection Walkthroughs: A Comprehensive Playbook The increasing reliance on electronic signatures in the pharmaceutical sector brings both efficiency and regulatory challenges, particularly during inspection…

Inadequate worst-case selection during inspection readiness – CAPA and revalidation strategy

Improving Worst-Case Selection for Enhanced Inspection Readiness In the highly regulated pharmaceutical industry, inadequate worst-case selection during inspection preparation can lead to significant compliance issues. As a professional engaged in…

Record retention failures during system operation – risk-based ERES remediation

Addressing Record Retention Failures during System Operations – A Comprehensive Playbook Record retention failures during system operation pose significant risks to data integrity and compliance within the pharmaceutical industry. These…

Incomplete validation lifecycle during inspection readiness – regulatory deficiency risk

Managing Incomplete Validation Lifecycle During Inspection Readiness to Mitigate Regulatory Deficiency Risks In a highly regulated pharmaceutical environment, maintaining a complete validation lifecycle is crucial for ensuring compliance and avoiding…

Record retention failures during system operation – inspection evidence requirements

Addressing Record Retention Failures During System Operation: An Inspection-Ready Playbook In the pharma manufacturing landscape, record retention failures can lead to significant operational challenges, especially during inspections. These failures can…

Change impact not assessed during inspection readiness – risk-based validation alignment

Assessment of Change Impact During Inspection Readiness: A Comprehensive Playbook In a highly regulated environment, the challenge of effectively assessing change impacts during inspection readiness poses significant risks to pharmaceutical…

Hybrid paper-electronic workflows uncontrolled during compliance audit – 21 CFR Part 11 compliance gaps

Managing Compliance Gaps in Hybrid Paper-Electronic Workflows During an Audit In the evolving landscape of pharmaceutical manufacturing, hybrid paper-electronic workflows pose significant challenges, particularly during compliance audits. When these workflows…

Requalification overdue during inspection readiness – regulatory deficiency risk

Addressing Requalification Delays During Inspection Readiness to Mitigate Regulatory Risks In the pharmaceutical landscape, regulatory compliance is not just critical; it is a cornerstone of operational integrity. A common issue…

ERES controls not implemented during validation lifecycle – preventing repeat Part 11 findings

Addressing ERES Control Failures During the Validation Lifecycle to Avoid Part 11 Findings In today’s pharmaceutical landscape, the integrity of electronic records and electronic signatures (ERES) is paramount. Failing to…

Change impact not assessed during inspection readiness – preventing repeat validation findings

Addressing Unassessed Change Impact During Inspection Preparedness to Avoid Recurrence of Validation Issues In pharmaceutical manufacturing, unaddressed changes can lead to critical compliance infringements, particularly during inspections. Auditors from FDA,…

System access controls weak during inspection walkthrough – preventing repeat Part 11 findings

Enhancing System Access Controls to Avoid Part 11 Findings During Inspections The integrity of pharmaceutical manufacturing processes heavily relies on stringent system access controls, especially in the context of electronic…